EntreMed Inc., of Rockville, Md., appointed Thomas H. Bliss senior vice president of corporate and business development...Lentigen Corp., of Baltimore, named Jim Meade vice president of corporate development

Javelin Pharmaceuticals Inc., of Cambridge, Mass., named Daniel Carr president and said Fred Mermelstein assumed the role of executive director...Oncothyreon Inc., of Bellevue, Wash., named Daniel K. Spiegelman and Stephen K. Burley to its board...Pantec Biosolutions AG, of Ruggell, Leichtenstein, appointed Burkhard Feurstein and Michael Armbruester to its board

Alphatec Holdings Inc., of Carlsbad, Calif., named Gary Fredericks vice president of corporate accounts and Mitsuo Asai president of its subsidiary, Alphatec Pacific Inc

and Timothy Maines vice president of corporate quality assurance

Jennerex Inc., of San Francisco, named Robert Ingram special advisor to the chairman and to president and CEO, and named Marty Glick executive vice president of corporate strategy

The firm also named Garen Manyelian chief medical officer and promoted Jennifer Marshall to vice president of corporate development

BiPar Sciences Inc., of Brisbane, Calif., named G. Kirk Raab acting CEO and appointed Eric Malek vice president of corporate development and Deborah Thomas vice president for regulatory affairs

Nitec Pharma AG, of Reinach, Switzerland, appointed Anders Harfstrand CEO and Andrea Buscaglia chief financial officer...Resolvyx Pharmaceuticals Inc., of Bedford, Mass., appointed James Nichols executive vice president of corporate development...Venrock, of Menlo Park, Calif., named Steve Goldby as partner and Ken Song as vice president

BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., appointed Joy Thomas vice president of corporate development...plc, of Dublin, Ireland, named Jonas Frick and Giles Kerr nonexecutive directors

Surface Logix, of Boston, appointed Leland Webster vice president of corporate development

Bavarian Nordic AS, of Kvistgard, Denmark, named Anders Hedegaard president and chief executive officer...Oscient Pharmaceuticals Corp., of Waltham, Mass., named Anthony Watkins vice president of corporate development

Ardea Biosciences Inc., of Carlsbad, Calif., appointed John Beck and John Poyhonen to its board of directors...vice president of research and development and chief scientific officer

Roger Ganser, acting CEO, has retired and will continue as chairman of the board of directors...Chromatin also appointed Caroline Kovac and John Hamer to its board of directors...Metabolix Inc., of Cambridge, Mass., named George Kipouras and Kristin Taylor business development managers, and Debra Darby brand director

Anadys Pharmaceuticals Inc., of San Diego, promoted Carol G. Gallagher to senior vice president of corporate development and commercial affairs...Cequent Pharmaceuticals, of Cambridge, Mass., named Johannes Fruehauf director of preclinical and clinical development

it appointed Kyle Keese senior vice president corporate affairs...and said Thomas Zink is assuming responsibility for clinical development in addition to medical affairs

as president and chief operating officer, and Kenneth Yonika, chief financial officer, secretary and treasurer

Pharmacyclics Inc., of Sunnyvale, Calif., appointed Michael Inouye senior vice president of corporate and commercial development

Neuralstem Inc., of Rockville, Md., appointed Scott Ogilvie and William Oldaker to its board...Craig Ritchie to chief European clinical adviser, and Robert Cherny to head of research...Protherics plc, of London, named Rolf Soderstrom finance director, and promoted President Saul Komisar to its board as an executive director

It also appointed Fred Krieger chief financial officer, Rohit Mehta vice president of corporate development, Joseph Crea executive director manufacturing and Hanna Zyruk director of regulatory affairs...and Eldon Smith, vice president, scientific affairs and director, will assume all responsibilities of the position of chief medical officer and head of cardiovascular development